0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
In This Issue of Archives of Internal Medicine |

In This Issue of Archives of Internal Medicine FREE

Arch Intern Med. 2003;163(12):1389. doi:10.1001/archinte.163.12.1389.
Text Size: A A A
Published online

MEDICATION ERRORS IN HOSPITALIZED CARDIOVASCULAR PATIENTS

The Institute of Medicine report To Err Is Human: Building a Safer Health System recommends pharmacist participation in patient rounds as an immediate approach to reducing medical errors. In the same report and in prior publications, cardiovascular drugs have been commonly associated with severe adverse drug events. Through a systematic review of the experience of a clinical pharmacist on the cardiology wards between 1995 and 2000, Allen LaPointe and Jollis classified medication errors according to the type of error, the medication(s) involved, the personnel involved, the stage(s) of drug administration involved, and the time of year most frequently associated with errors. The transition from outpatient to inpatient was identified as the most common point in the system for the occurrence of medication errors. In addition, higher numbers of errors were identified during the transition periods of house staff. The development of better systems to communicate and maintain medication information between ambulatory and hospital settings appears critical in reducing medication errors during hospitalization. Improved education and support of new interns during their initial months of training also appears to be important in reducing medication errors. Clinical pharmacists are uniquely qualified to provide support in both of these areas to reduce medication errors.

See Article

RELATIONSHIP OF WALKING TO MORTALITY AMONG US ADULTS WITH DIABETES

Few studies have examined the long-term impact of physical activity among people with type 2 diabetes mellitus. In a nationally representative sample of persons with type 2 diabetes, Gregg et al examined the association of walking and other physical activities on 8-year all-cause and cardiovascular mortality. Persons who reported walking at least 2 hours per week had a 39% lower mortality rate than sedentary persons (when controlled for sex, age, race, body mass index, smoking, and health status). The mortality rate was lowest (56% less) for persons who walked 3 to 4 hours per week and for those who reported that their walking involved moderate increases in heart rate and breathing. The protective association was observed for persons with diverse demographic characteristics, diabetes duration, and comorbid conditions. These findings suggest that increasing walking should be a major part of programs to reduce the burden of type 2 diabetes.

See Article

PROGRESSION OF CHRONIC RENAL FAILURE

Chronic renal failure is characterized by a persistently abnormal glomerular filtration rate. The rate of progression varies substantially. Several morphologic features are prominent: fibrosis, loss of native renal cells, and infiltration by monocytes and/or macrophages. Mediators of the process include abnormal glomerular hemodynamics, hypoxia, proteinuria, hypertension, and several vasoactive substances (ie, cytokines and growth factors). Several predisposing host factors may also contribute to the process. Treatments to delay progression are aimed at treating the primary disease and at strictly controlling the systemic blood pressure and proteinuria. In this article, Yu discusses the processes that affect progression after the initial renal insult has occurred and the role of antihypertensive agents, statins, and use of other maneuvers such as protein restriction and novel approaches.

See Article

CHOLESTEROL-LOWERING EFFECT OF A THEAFLAVIN-ENRICHED GREEN TEA EXTRACT

Maron et al studied the impact of a theaflavin-enriched green tea extract on the lipid and lipoprotein levels of subjects with mild to moderate hypercholesterolemia in a double-blind, randomized, placebo-controlled, parallel-group trial in China. A total of 240 men and women 18 years or older on a low-fat diet with mild to moderate hypercholesterolemia were randomly assigned to receive a daily capsule containing theaflavin-enriched green tea extract (375 mg) or placebo for 12 weeks. Main outcome measures were mean percentage changes in total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglyceride levels compared with baseline. The results are shown in Figure 1. The authors conclude that the theaflavin-enriched green tea extract used in their study is an effective adjunct to a low-saturated-fat diet to lower low-density lipoprotein cholesterol levels in adults with hypercholesterolemia and is well tolerated.

Place holder to copy figure label and caption

Asterisk indicates P<.01 compared with baseline; dagger, P<.001 compared with baseline.

Graphic Jump Location

See Article

Figures

Place holder to copy figure label and caption

Asterisk indicates P<.01 compared with baseline; dagger, P<.001 compared with baseline.

Graphic Jump Location

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.